Watch on earnings: Quarterly Barostim implant volumes and year-over-year growth acceleration, Active implanting center count and geographic expansion (currently concentrated in select US markets), Medicare reimbursement rate changes and coverage policy updates from CMS.
One Sentence Summary:
CVRx: the story is balanced — quarterly implant volumes and sequential growth trends (currently estimated 200-250 annual implants).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.